A randomized, controlled trial of prulifloxacin as conversion therapy after intravenous carbapenem in the treatment of acute pyelonephritis caused by third generation cephalosporin resistant pathogens: A pilot study
Abstract The efficacy of converting to oral fluoroquinolones after initial intravenous antibiotics for the treatment of acute pyelonephritis (APN) caused by the third‐generation cephalosporin resistant Enterobacteriaceae (3‐GCrEC) needs to be investigated. The objective was to compare the clinical a...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2023-12-01
|
| Series: | Clinical and Translational Science |
| Online Access: | https://doi.org/10.1111/cts.13665 |
| _version_ | 1797391737465864192 |
|---|---|
| author | Apichot So‐Ngern Supunnee Jirajariyavej Huttaya Thuncharoon Nuttha Khunthupat Teerachai Chantarojanasiri Preecha Montakantikul |
| author_facet | Apichot So‐Ngern Supunnee Jirajariyavej Huttaya Thuncharoon Nuttha Khunthupat Teerachai Chantarojanasiri Preecha Montakantikul |
| author_sort | Apichot So‐Ngern |
| collection | DOAJ |
| description | Abstract The efficacy of converting to oral fluoroquinolones after initial intravenous antibiotics for the treatment of acute pyelonephritis (APN) caused by the third‐generation cephalosporin resistant Enterobacteriaceae (3‐GCrEC) needs to be investigated. The objective was to compare the clinical and bacteriological outcome of oral prulifloxacin with intravenous ertapenem for the treatment of APN caused by 3‐GCrEC. A pilot, randomized controlled trial of patients with APN caused by 3‐GCrEC was conducted at two hospitals from August 2015 to December 2020. Any intravenous antimicrobial drug was initially permitted for empirical therapy. On day 4, adult patients (aged >18 years) with either non‐bacteremic or bacteremic APN were eligible for the study if their infection was caused by 3‐GCrEC susceptible to the study drugs. The patients were randomly assigned to receive either oral prulifloxacin or intravenous ertapenem. The total duration of antimicrobial therapy was 14 days. Of the 21 enrolled patients, 11 were treated with prulifloxacin, and 10 were treated with ertapenem. At the test of cure visit, there was no statistically significant difference between the patients with overall clinical success who were treated with prulifloxacin (90.9%) and those treated with ertapenem (100%, p = 0.999). In addition, there was no statistically significant difference in microbiological eradication between the prulifloxacin and ertapenem groups (100% vs. 100%, p = 0.999). The converting to oral prulifloxacin after intravenous antibiotics therapy appears to be an alternative option for treatment of APN caused by 3‐GCrEC. A further large randomized controlled trial should be investigated. |
| first_indexed | 2024-03-08T23:37:00Z |
| format | Article |
| id | doaj.art-a35f49def72341ee848794c77ed76d17 |
| institution | Directory Open Access Journal |
| issn | 1752-8054 1752-8062 |
| language | English |
| last_indexed | 2024-03-08T23:37:00Z |
| publishDate | 2023-12-01 |
| publisher | Wiley |
| record_format | Article |
| series | Clinical and Translational Science |
| spelling | doaj.art-a35f49def72341ee848794c77ed76d172023-12-14T06:03:04ZengWileyClinical and Translational Science1752-80541752-80622023-12-0116122709271810.1111/cts.13665A randomized, controlled trial of prulifloxacin as conversion therapy after intravenous carbapenem in the treatment of acute pyelonephritis caused by third generation cephalosporin resistant pathogens: A pilot studyApichot So‐Ngern0Supunnee Jirajariyavej1Huttaya Thuncharoon2Nuttha Khunthupat3Teerachai Chantarojanasiri4Preecha Montakantikul5Faculty of Pharmacy Siam University Bangkok ThailandDepartment of Medicine Taksin Hospital Bangkok ThailandMicrobiology Laboratory Taksin Hospital Bangkok ThailandDepartment of Pharmacy Taksin Hospital Bangkok ThailandBhumirajanagarindra Kidney Institute Bangkok ThailandDepartment of Pharmacy Faculty of Pharmacy Mahidol University Bangkok ThailandAbstract The efficacy of converting to oral fluoroquinolones after initial intravenous antibiotics for the treatment of acute pyelonephritis (APN) caused by the third‐generation cephalosporin resistant Enterobacteriaceae (3‐GCrEC) needs to be investigated. The objective was to compare the clinical and bacteriological outcome of oral prulifloxacin with intravenous ertapenem for the treatment of APN caused by 3‐GCrEC. A pilot, randomized controlled trial of patients with APN caused by 3‐GCrEC was conducted at two hospitals from August 2015 to December 2020. Any intravenous antimicrobial drug was initially permitted for empirical therapy. On day 4, adult patients (aged >18 years) with either non‐bacteremic or bacteremic APN were eligible for the study if their infection was caused by 3‐GCrEC susceptible to the study drugs. The patients were randomly assigned to receive either oral prulifloxacin or intravenous ertapenem. The total duration of antimicrobial therapy was 14 days. Of the 21 enrolled patients, 11 were treated with prulifloxacin, and 10 were treated with ertapenem. At the test of cure visit, there was no statistically significant difference between the patients with overall clinical success who were treated with prulifloxacin (90.9%) and those treated with ertapenem (100%, p = 0.999). In addition, there was no statistically significant difference in microbiological eradication between the prulifloxacin and ertapenem groups (100% vs. 100%, p = 0.999). The converting to oral prulifloxacin after intravenous antibiotics therapy appears to be an alternative option for treatment of APN caused by 3‐GCrEC. A further large randomized controlled trial should be investigated.https://doi.org/10.1111/cts.13665 |
| spellingShingle | Apichot So‐Ngern Supunnee Jirajariyavej Huttaya Thuncharoon Nuttha Khunthupat Teerachai Chantarojanasiri Preecha Montakantikul A randomized, controlled trial of prulifloxacin as conversion therapy after intravenous carbapenem in the treatment of acute pyelonephritis caused by third generation cephalosporin resistant pathogens: A pilot study Clinical and Translational Science |
| title | A randomized, controlled trial of prulifloxacin as conversion therapy after intravenous carbapenem in the treatment of acute pyelonephritis caused by third generation cephalosporin resistant pathogens: A pilot study |
| title_full | A randomized, controlled trial of prulifloxacin as conversion therapy after intravenous carbapenem in the treatment of acute pyelonephritis caused by third generation cephalosporin resistant pathogens: A pilot study |
| title_fullStr | A randomized, controlled trial of prulifloxacin as conversion therapy after intravenous carbapenem in the treatment of acute pyelonephritis caused by third generation cephalosporin resistant pathogens: A pilot study |
| title_full_unstemmed | A randomized, controlled trial of prulifloxacin as conversion therapy after intravenous carbapenem in the treatment of acute pyelonephritis caused by third generation cephalosporin resistant pathogens: A pilot study |
| title_short | A randomized, controlled trial of prulifloxacin as conversion therapy after intravenous carbapenem in the treatment of acute pyelonephritis caused by third generation cephalosporin resistant pathogens: A pilot study |
| title_sort | randomized controlled trial of prulifloxacin as conversion therapy after intravenous carbapenem in the treatment of acute pyelonephritis caused by third generation cephalosporin resistant pathogens a pilot study |
| url | https://doi.org/10.1111/cts.13665 |
| work_keys_str_mv | AT apichotsongern arandomizedcontrolledtrialofprulifloxacinasconversiontherapyafterintravenouscarbapeneminthetreatmentofacutepyelonephritiscausedbythirdgenerationcephalosporinresistantpathogensapilotstudy AT supunneejirajariyavej arandomizedcontrolledtrialofprulifloxacinasconversiontherapyafterintravenouscarbapeneminthetreatmentofacutepyelonephritiscausedbythirdgenerationcephalosporinresistantpathogensapilotstudy AT huttayathuncharoon arandomizedcontrolledtrialofprulifloxacinasconversiontherapyafterintravenouscarbapeneminthetreatmentofacutepyelonephritiscausedbythirdgenerationcephalosporinresistantpathogensapilotstudy AT nutthakhunthupat arandomizedcontrolledtrialofprulifloxacinasconversiontherapyafterintravenouscarbapeneminthetreatmentofacutepyelonephritiscausedbythirdgenerationcephalosporinresistantpathogensapilotstudy AT teerachaichantarojanasiri arandomizedcontrolledtrialofprulifloxacinasconversiontherapyafterintravenouscarbapeneminthetreatmentofacutepyelonephritiscausedbythirdgenerationcephalosporinresistantpathogensapilotstudy AT preechamontakantikul arandomizedcontrolledtrialofprulifloxacinasconversiontherapyafterintravenouscarbapeneminthetreatmentofacutepyelonephritiscausedbythirdgenerationcephalosporinresistantpathogensapilotstudy AT apichotsongern randomizedcontrolledtrialofprulifloxacinasconversiontherapyafterintravenouscarbapeneminthetreatmentofacutepyelonephritiscausedbythirdgenerationcephalosporinresistantpathogensapilotstudy AT supunneejirajariyavej randomizedcontrolledtrialofprulifloxacinasconversiontherapyafterintravenouscarbapeneminthetreatmentofacutepyelonephritiscausedbythirdgenerationcephalosporinresistantpathogensapilotstudy AT huttayathuncharoon randomizedcontrolledtrialofprulifloxacinasconversiontherapyafterintravenouscarbapeneminthetreatmentofacutepyelonephritiscausedbythirdgenerationcephalosporinresistantpathogensapilotstudy AT nutthakhunthupat randomizedcontrolledtrialofprulifloxacinasconversiontherapyafterintravenouscarbapeneminthetreatmentofacutepyelonephritiscausedbythirdgenerationcephalosporinresistantpathogensapilotstudy AT teerachaichantarojanasiri randomizedcontrolledtrialofprulifloxacinasconversiontherapyafterintravenouscarbapeneminthetreatmentofacutepyelonephritiscausedbythirdgenerationcephalosporinresistantpathogensapilotstudy AT preechamontakantikul randomizedcontrolledtrialofprulifloxacinasconversiontherapyafterintravenouscarbapeneminthetreatmentofacutepyelonephritiscausedbythirdgenerationcephalosporinresistantpathogensapilotstudy |